Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad Genetics's Other Operating Expense for the
three
months ended in Jun. 2026 was €0.0 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €0.0 Mil.
Myriad Genetics's quarterly Other Operating Expense
increased
from Dec. 2025 (€0.0 Mil) to Mar. 2026 (€0.0 Mil) but then
declined
from Mar. 2026 (€0.0 Mil) to Jun. 2026 (€0.0 Mil).
Myriad Genetics Other Operating Expense Related Terms
Myriad Genetics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €0.0 Mil mean?
Myriad Genetics (FRA:MYD) has a Other Operating Expense of €0.0 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Other Operating Expense too high?
Myriad Genetics' current Other Operating Expense is €0.0 Mil. Overall, Myriad Genetics has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Other Operating Expense compare to FLGT and CSTL?
Myriad Genetics' Other Operating Expense of €0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Diagnostics & Research company?
A good Other Operating Expense depends on the Medical Diagnostics & Research industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Other Operating Expense is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €12.24, compared to a current price of €4.33 — trading 64.7% below its estimated fair value. The current Other Operating Expense is €0.0 Mil. Myriad Genetics' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current Other Operating Expense is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (FRA:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €4.33 is trading 64.7% below its estimated GF Value™ of €12.24.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for FRA:MYD:
Other Operating Expense: €0.0 Mil
GF Value™: €12.24 vs. price of €4.33 (64.7% below fair value)
No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
58GF Score
Get the complete analysis for FRA:MYD
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MYD has been successfully added to your 
